Relationship between recurrent colorectal cancer and EGFR inhibitor-induced dermatological side effects: a focus on paronychia
Abstract
This case describes a woman in her mid-40s with recurrent colorectal cancer who developed severe dermatologic toxicity during panitumumab-based therapy. Three months after treatment initiation, she developed a diffuse acneiform eruption, pronounced xerosis and painful periungual inflammation with exuberant granulation tissue consistent with epidermal growth factor receptor (EGFR)-inhibitor-induced paronychia. Multidisciplinary, guideline-concordant supportive care (including prompt topical measures and short-course systemic therapy) achieved symptom control and allowed continuation of anticancer treatment. This report underscores the importance of early recognition and structured management of EGFR-inhibitor toxicities to prevent treatment disruption and preserve quality of life.
Fields of Study & Subjects
Colorectal Cancer Treatments and Studies
Chemotherapy-related skin toxicity
Hidradenitis Suppurativa and Treatments
Publication details
- Journal / source
- BMJ Case Reports
- Publisher
- BMJ
- Volume
- 19
- Issue
- 1
- Pages
- e266250–e266250
- Publication date
- 1 January 2026
- Language
- EN